Published in Blood Weekly, March 31st, 1997
DCLHb, a hemoglobin-based blood substitute developed by Baxter Healthcare Corporation, USA, has been found to increase mean arterial pressure (MAP) in a dose limiting manner, noted Abhijit Barve, the University of Illinois at Chicago, Chicago, Illinois, and colleagues.
Barve et al. performed a study to determine dose-dependent effects of DCLHb on systemic hemodynamics and regional blood circulation ("Dose Response Effect of Diaspirin Crosslinked Hemoglobin (DCLHb) on Systemic Hemodynamics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.